Average weekly weight loss on Mounjaro: what the trial data actually shows

The misconception: a steady, predictable number every week

Most people searching this question have the same hope: that there is one clean number (say, 0.5 kg a week) that Mounjaro reliably delivers. It is an understandable way to think about it. The reality is more useful to know, even if it is less tidy.

Weight loss on tirzepatide is not a straight line. In the first weeks after starting, many people see relatively quick movement on the scales, partly from reduced water retention and lower calorie intake as appetite settles. Then things slow. A plateau in weeks four to eight is not a sign treatment has stopped working; it is the body recalibrating. Over the full 72 weeks of SURMOUNT-1, the average shakes out to roughly 0.3–0.5 kg per week, but that average spans periods of faster loss and flatter stretches. Understanding how long Mounjaro takes to work matters as much as the weekly number itself.

The bigger myth is that the weekly rate stays constant as doses increase. In practice, the titration schedule (starting at 2.5 mg and stepping up, typically every four weeks) means average weekly loss also changes over time as the therapeutic dose builds. The starter pen is there to help your digestive system adjust, not to drive weight loss.

What the SURMOUNT-1 data actually shows, dose by dose

SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity but without type 2 diabetes to tirzepatide or placebo for 72 weeks. All participants followed a reduced-calorie diet and increased physical activity alongside treatment. At 72 weeks, the average body-weight reduction was around 15% at 5 mg, around 19.5% at 10 mg, and around 20–22% at 15 mg.

Translated into a weekly figure: if someone starts at 100 kg and loses 20% over 72 weeks, that is 20 kg across 72 weeks, or roughly 0.28 kg per week on average. At 22% and a heavier starting weight the number rises. This is why stating a single average weekly weight loss on tirzepatide requires a starting-weight assumption, the percentage is the cleaner fact.

NICE reviewed this evidence thoroughly in its appraisal of tirzepatide (TA1026) and concluded the medicine represents an effective option for eligible adults. The committee also noted that SURMOUNT-5 found tirzepatide produced greater average weight reduction than semaglutide 2.4 mg head-to-head, though individual responses vary.

For a fuller picture of how total weight loss figures compare across the programme, the overall average weight loss on Mounjaro page covers the evidence in more depth.

Why your own weekly average will look different from the trial

Trial conditions and real life diverge in ways that matter. SURMOUNT-1 participants had structured dietary coaching, regular check-ins and no access issues with their medication. Most people using Mounjaro privately do not have a dietitian calling every fortnight.

Several factors push your personal weekly average up or down: starting weight (heavier starting points often mean faster absolute loss early on), which maintenance dose you reach and tolerate, how consistently you follow a reduced-calorie approach, your baseline activity, and whether gastrointestinal side effects in the early weeks affected your intake. One question our prescribers hear regularly is whether a slow first few weeks means something has gone wrong, usually, it has not.

If you are thinking about what Mounjaro costs relative to what it delivers, it is worth reading the context on the Eli Lilly UK price increase page, which explains how private market pricing works. Separately, the first week's data can help calibrate expectations right at the start of treatment.

Mounjaro is a prescription-only medicine: a clinician reviews your health history, current medicines and BMI before prescribing. The weight-loss treatment overview covers the full range of options available through a regulated UK pharmacy if you are still deciding which route suits you.

The right way to track progress on a weekly basis

Weekly weigh-ins have genuine value (they keep you honest and let your prescriber spot a plateau early) but a single week's reading is noise. Weighing at the same time each day (first thing in the morning works well for most people) and tracking a rolling four-week average gives a much cleaner picture than Tuesday-to-Tuesday comparisons.

Total centimetres lost, energy levels, blood pressure readings and how clothes fit are all signals that weekly scales data misses. In SURMOUNT-1, improvements in cardiometabolic markers appeared alongside weight changes, suggesting the medicine's effects run broader than the number on the scales alone.

The weekly weight loss on Mounjaro page goes further into how to interpret week-by-week changes sensibly. And if you want to compare tirzepatide's trajectory against semaglutide data, average weight loss on tirzepatide lays out the cross-trial picture. When you are ready to see whether Mounjaro is appropriate for you, check your eligibility with our prescribers, the consultation is free, and a real clinician reviews your answers the same day.